BiotechTube

exidavnemab + Placebo Comparator

Phase 2Active
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Multiple System Atrophy

Trial Timeline

Oct 24, 2024 → Aug 17, 2026

NCT ID
NCT06671938

About exidavnemab + Placebo Comparator

exidavnemab + Placebo Comparator is a phase 2 stage product being developed by BioArctic AB for Parkinson Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06671938. Target conditions include Parkinson Disease, Multiple System Atrophy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06671938Phase 2Active

Competing Products

20 competing products in Parkinson Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
LY4006896 + PlaceboEli LillyPhase 1
33
ATH-1017 + PlaceboLeonaBioPhase 2
44
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
Mirabegron + PlaceboAstellas PharmaApproved
85
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
Equfina 50 mgEisaiPre-clinical
23
EqufinaEisaiPre-clinical
23
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
Safinamide MesilateEisaiApproved
85
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52